Sarepta: HC Wainwright Downgrades to Sell with $10 PT.

Sarepta: HC Wainwright Downgrades to Sell with $10 PT.

Sarepta Therapeutics (SRPT) has faced a significant setback after HC Wainwright analyst Mitchell Kapoor downgraded the stock to a "Sell" rating, slashing the price target to $10. This move comes amid growing safety concerns over Sarepta's flagship gene therapy, Elevidys, which has seen a series of analyst downgrades and a sharp sell-off in recent weeks [2].

The latest downgrade from HC Wainwright follows a wave of analyst caution, with Piper Sandler, Morgan Stanley, and Needham also cutting their ratings and price targets for Sarepta. These developments underscore the challenges faced by Sarepta in navigating the safety concerns and potential market impacts of its Elevidys treatment [2].

Despite the recent turmoil, some investors see the pullback as a strategic entry point, given Sarepta's first-mover advantage in Duchenne muscular dystrophy treatment. However, the stock remains a high-risk, high-reward play, with a possible 200% rebound on the table if it can address safety issues and regain market confidence [2].

According to TipRanks, Wall Street has a Moderate Buy consensus rating on SRPT stock, based on 15 Buys, nine Holds, and one Sell assigned in the last three months. The average SRPT stock price target of $64.50 implies a 199.17% upside potential [2].

Sarepta is focused on developing genetic medicines to treat rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD). The company reported a second fatal case of acute liver failure linked to Elevidys, prompting Sarepta to suspend shipments for non-ambulatory patients [2].

Investors should closely monitor Sarepta's progress in addressing safety concerns and the potential regulatory implications. The company's ability to regain market confidence and deliver on its long-term growth narrative will be crucial for its stock performance [2].

References:
[1] https://www.marketbeat.com/instant-alerts/hc-wainwright-has-bullish-estimate-for-dgxx-q2-earnings-2025-06-16/
[2] https://www.theglobeandmail.com/investing/markets/stocks/RHHBY/pressreleases/32958668/sarepta-stock-srpt-could-soar-200-despite-growing-caution-on-wall-street/
[3] https://www.investing.com/news/analyst-ratings/william-blair-downgrades-sarepta-stock-rating-on-limited-revenue-potential-93CH-4103492
[4] https://www.gurufocus.com/news/2943195/sangamo-therapeutics-sgmo-receives-reiterated-buy-rating-from-hc-wainwright-co-sgmo-stock-news